Pauline Anderson

Pauline Anderson is a researcher at the University of California, Los Angeles. She has published several articles on topics related to mental health and trauma. In her free time, she enjoys hiking and spending time with her family.

Biography:  https://www.medscape.com/viewarticle/991452

58%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

10%

Examples:

  • The author has a bias towards presenting the findings of their research in an objective and unbiased manner.

Conflicts of Interest

50%

Examples:

  • The author does not have any clear conflicts of interest in this article.

Contradictions

85%

Examples:

  • Continuing aspirin was causing harm without providing any benefit as there was no increase in adverse ischemic events when folks stopped using it early. This contradicts previous research that has found aspirin to be beneficial for preventing cardiovascular disease.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Study Finds Aspirin Reduces Bleeding Complications After PCI for Heart Attack Patients

New Study Finds Aspirin Reduces Bleeding Complications After PCI for Heart Attack Patients

Broke On: Tuesday, 09 April 2024 A new study published in The Lancet found that stopping aspirin one month after percutaneous coronary intervention (PCI) for an acute coronary syndrome significantly reduces bleeding complications in heart attack patients. This is the first time a placebo-controlled trial has confirmed this finding, and it was presented at the American College of Cardiology 2024 Scientific Sessions on Sunday, April 7th.